Zacks Bull and Bear of the Day Highlights: Genentech, Primus Guaranty, Power Integrations, Unibanco and Amdocs

Full analysis of all these stocks is available at http://at.zacks.com/?id=2676.

Here is a synopsis of all five stocks:

Bull of the Day: Genentech (NYSE: DNA)

We are reiterating our rating on Genentech at Buy, and moving our target price to $90 / share. We remind investors that we upgraded the name in February 2008 based on the Accelerated Approval of Avastin for 1st-line metastatic breast cancer. Avastin sales in the second quarter were solid, and we expect the trend to continue well into 2009.

Genentech is the world's premier biotechnology company. The stock has struggled over the past several quarters. However, the pipeline is solid and with renewed Avastin and Rituxan growth, the valuation looks very attractive at this level. We view the name as a core healthcare holding.

Bear of the Day: Primus Guaranty (NYSE: PRS)

We anticipate that higher provisions and mark-to-market losses due to challenging credit environment will impact the results in the coming quarters, though the company may be able to grow its credit protection business at attractive prices as the credit spreads continue to widen. Based on our concerns, we are maintaining our Sell recommendation on the shares of PRS and lowering our six-month target price to $2.50 per share.

Latest Posts on the Zacks Analyst Blog:

Power Integrations, Inc. (Nasdaq: POWI)

Power Integrations is an original equipment manufacturer (OEM) of semiconductor power conversion ICs. The California Energy Commission recently (CEC) pushed out an industry mandate that should create an earnings catalyst for the company in 2008. A solid product portfolio, new patents and product launches, along with the recently adopted worldwide energy standards should drive growth.

The timing and magnitude of the revenue growth, along with ongoing legal expenses are over hangs on the stock. We remain cautious and rate shares of POWI a Hold. We are setting a target price of $33.00, which corresponds to a P/E multiple of 22.0x.

Unibanco S.A. (NYSE: UBB)

We are retaining our Buy rating on Unibanco Uniao de Bancos Brasileiros S.A., the fourth largest private bank in Brazil. UBB represents a good value relative to its strong growth prospects and also vis-a-vis-Brazilian peers.

UBB will report second quarter results on August 8. We are raising our EPGDS estimates to $13.00 from $12.75 for 2008 and to $15.00 from $14.75 for 2009, due to a change in our foreign currency assumptions related to depreciation of the US$ against the Brazilian R$.

Amdocs, Ltd. (NYSE: DOX)

We maintain our Buy recommendation and the same valuation target for Amdocs Ltd., a leading provider of CRM and billing software for telecom carriers, as the company will shortly declare third quarter (ended June 30) fiscal 2008 financial results. We believe the long-run fundamentals for the company remain strong as Amdocs continues to benefit from large transformation projects at many telephone carriers requiring converged and consolidated network solutions.

Get the most recent insight from Zacks Equity Research with the free Profit from the Pros newsletter: http://at.zacks.com/?id=2649.

About the Bull and Bear of the Day

Every day, the analysts at Zacks Equity Research select two stocks that are likely to outperform (Bull) or underperform (Bear) the markets over the next 3-6 months.

About the Analyst Blog

Updated throughout every trading day, the Analyst Blog provides analysis from Zacks Equity Research about the latest news and events impacting stocks and the financial markets.

About Zacks Equity Research

Zacks Equity Research provides the best of quantitative and qualitative analysis to help investors know what stocks to buy and which to sell for the long-term.

Continuous coverage is provided for a universe of 1,150 publicly traded stocks. Our analysts are organized by industry which gives them keen insights to developments that affect company profits and stock performance. Recommendations and target prices are six-month time horizons.

Zacks "Profit from the Pros" e-mail newsletter provides highlights of the latest analysis from Zacks Equity Research. Subscribe to this free newsletter today by visiting http://at.zacks.com/?id=2677.

About Zacks

Zacks.com is a property of Zacks Investment Research, Inc., which was formed in 1978 by Leonard Zacks. As a PhD in mathematics Len knew he could find patterns in stock market data that would lead to superior investment results. Amongst his many accomplishments was the formation of his proprietary stock picking system; the Zacks Rank, which continues to outperform the market by nearly a 3 to 1 margin. The best way to unlock the profitable stock recommendations and market insights of Zacks Investment Research is through our free daily email newsletter; Profit from the Pros. In short, it's your steady flow of Profitable ideas GUARANTEED to be worth your time! Register for your free subscription to Profit from the Pros at http://at.zacks.com/?id=4582.

Visit http://www.zacks.com/performance for information about the performance numbers displayed in this press release.

Disclaimer: Past performance does not guarantee future results. Investors should always research companies and securities before making any investments. Nothing herein should be construed as an offer or solicitation to buy or sell any security.

SOURCE: Zacks.com

Zacks.com Mark Vickery 312-265-9380 Visit: www.zacks.com